Need-to-Know Endocrinology Updates
In this episode, we cover the most important developments shaping the future of metabolic health, including new treatments, real-world data insights, global trends, and clinical innovations.
🔬 Highlights this week include:
– CuraTeQ’s denosumab biosimilar shows bioequivalence in Phase 1 trials
– Global CPR launched by IDF for Type 2 diabetes care
– Oral semaglutide cuts major cardiovascular risk by 14 percent overall—and 27 percent in Asian patients
– Real-world tirzepatide use slower than expected, impacting outcomes
– New sex-based bone regeneration insights may shape personalized therapies
– Glucosamine linked to lower kidney risk in people with T2D
– Poland reports Europe’s sharpest spike in pediatric Type 1 diabetes
– Protein discovery may reduce or eliminate insulin use
– Cognitive and glycemic improvements seen with Cdk5 inhibitor in preclinical trials
– Dexcom G7 CGM cleared by FDA for extended 15-day use with improved accuracy
Whether you’re a clinician, researcher, or healthcare strategist, this update delivers actionable insights into the evolving endocrinology landscape.
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on diabetes, obesity, and metabolic health
#Endocrinology #DiabetesCare #ClinicalResearch #T2D #T1D #CardiometabolicHealth #PharmaNews #LucidQuest #MedicalInnovation #GlucoseMonitoring #DigitalHealth